ARMGO Pharma, Inc. (ARMGO), a clinical stage biopharmaceutical company advancing a novel class of small molecule drugs known as Rycals®, announced today the enrollment of the first patient in a Phase ...
Solid Biosciences announces Phase 1b trial for SGT-501, a gene therapy for catecholaminergic polymorphic ventricular tachycardia, with FDA designations. Solid Biosciences Inc. has announced the ...
CHARLESTOWN, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and ...
- Potential first-in-class therapy with FDA IND clearance and Health Canada CTA approval designed to address underlying causes of CPVT, a life-threatening, arrhythmogenic cardiac condition - - Solid ...
Researchers have developed a novel method for simultaneously recording action potentials (APs)—temporary changes in electrical potential when cells become excited—and calcium transients—calcium ...
Ventricular tachycardia arises from an abnormal electrical focus or circuit in the myocardium of the ventricle and is usually manifested as a tachyarrhythmia with a wide QRS complex on ...
As reviewed earlier, termination of reentrant tachycardia requires critical timing of the pacing stimulus. Success or failure of the pacing stimulus to interact with and terminate tachycardia, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results